Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Adverse events with IL-17 and IL-23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta-analysis of phase III studies

Research output: Contribution to journalReviewpeer-review

DOI

  1. Clinical characteristics including cardiovascular and metabolic risk factors in adolescents with psoriasis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Obesity as a risk factor for psoriasis

    Research output: Contribution to journalEditorialpeer-review

  3. Atopic dermatitis is associated with increased use of social benefits: a register-based cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Association between vascular inflammation and inflammation in adipose tissue, spleen, and bone marrow in patients with psoriasis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Presence of streptococci and frequent tonsillitis among adolescents with psoriasis

    Research output: Contribution to journalLetterpeer-review

  3. Vaccination against PD-L1 with IO103 a Novel Immune Modulatory Vaccine in Basal Cell Carcinoma: A Phase IIa Study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Biologics targeting interleukin (IL)-17 and IL-23 are generally well-tolerated and considered safe, though adverse events are seen more often compared with placebo. The objectives of this systematic review and meta-analysis were to assess the prevalence of adverse events in patients with psoriasis or psoriatic arthritis with any adverse events after 12, 16, 24 and 52 weeks of treatment with IL-17 or IL-23 inhibitors. Two independent authors searched the databases PubMed and EMBASE for studies reporting on adverse events in phase 3 trials of IL-17 and IL-23 inhibitors for patients with psoriasis and psoriatic arthritis. The study was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Data synthesis was performed using a random-effects model. In total, 44 publications (43 studies) were included in the analyses. The proportion of patients with any adverse events for all treatments pooled were 0.57 [95% confidence interval (CI): 0.55-0.59] after 12 weeks, 0.52 (95% CI: 0.49-0.55) after 16 weeks, 0.72 (95% CI: 0.66-0.78) after 24 weeks and 0.81 (95% CI: 0.76-0.86) after 52 weeks. Across therapies, the most prevalent AEs were infections, nasopharyngitis and headache. For ixekizumab one of the most prevalent AEs was injection site reactions, reported in 15.7% of the patients after 52 weeks. Overall, IL-17 and IL-23 inhibitors appear to be well-tolerated with good safety profiles. Our findings may aid the clinical decision making when choosing the most appropriate therapy for patients with moderate-to-severe psoriasis.

Original languageEnglish
JournalJournal of the European Academy of Dermatology and Venereology : JEADV
Volume34
Issue number6
Pages (from-to)1151-1160
Number of pages10
ISSN0926-9959
DOIs
Publication statusPublished - Jun 2020

ID: 61761887